Overview
Glucose-6-phosphate dehydrogenase (G6PD) deficiency in adults, particularly affecting leukocytes, predisposes individuals to acute hemolytic anemia under oxidative stress conditions, often triggered by certain medications 1.Diagnosis
Genetic Testing: Use G6PD genotype testing for definitive diagnosis 1.
Phenotypic Assessment: Not explicitly detailed; genotype testing is prioritized 1.Management
Avoid High-Risk Medications: Steer clear of drugs classified as high risk for G6PD deficiency 1.
Use Caution with Medium-Risk Medications: Administer with caution and monitor closely 1.
Standard Precautions for Low-Risk Medications: Use as indicated without special G6PD considerations 1.Special Populations
No Specific Guidance Provided: Abstracts do not cover special populations such as pregnancy, pediatrics, elderly, or comorbidities 1.Key Recommendations
Utilize G6PD Genotype Testing for Risk Stratification: Classify medications as high, medium, or low risk based on genotype to guide therapy (Evidence: Moderate) 1.
Avoid High-Risk Medications in G6PD Deficient Patients: To prevent acute hemolytic anemia (Evidence: Moderate) 1.
Exercise Caution with Medium-Risk Medications: Monitor closely for signs of hemolysis (Evidence: Weak) 1.References
1 Gammal RS, Pirmohamed M, Somogyi AA, Morris SA, Formea CM, Elchynski AL et al.. Expanded Clinical Pharmacogenetics Implementation Consortium Guideline for Medication Use in the Context of G6PD Genotype. Clinical pharmacology and therapeutics 2023. link